Overview: APOE Genotyping TestIntroduction: The APOE Genotyping Test analyzes APOE gene variants to assess risk of Alzheimer's disease or heart disease, which may cause memory loss or heart problems. Aligned with 2023 ACMG guidelines, it uses PCR for high specificity, aiding in genetic screening. This test is critical for guiding risk assessment, preventive strategies, and improving outcomes in molecular pathology for patients with suspected genetic predispositions.
Other Names: APOE Assay, Apolipoprotein E Genotyping Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: APOE genotyping began in the 1990s with Alzheimer's research. PCR-based assays emerged in the 2000s, and by the 2010s, high-sensitivity methods improved risk assessment for Alzheimer's and heart disease.
Purpose: Assesses risk of Alzheimer's or heart disease, guides preventive strategies, and monitors genetic predisposition in patients with memory loss or heart problems.
Test Parameters: 1. APO E Genotype
Pretest Condition: Fasting for 10-12 hours required to stabilize DNA extraction. Collect whole blood, buccal swab, or saliva after overnight fasting. Report symptoms like memory loss or heart issues, and list medications like statins.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document neurological or cardiovascular symptoms, family history of Alzheimer's or heart disease. Include current medications, especially statins or cognitive enhancers.
Consent: Written consent required, detailing the tests purpose, implications for risk assessment, and potential need for genetic counseling.
Procedural Considerations: Uses PCR to analyze APOE gene variants (e2, e3, e4). Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Improper storage or delayed transport can degrade DNA. Contamination or low sample quality may affect PCR sensitivity.
Clinical Significance: APOE e4 variant indicates increased Alzheimer's or heart disease risk, prompting preventive measures. Other variants suggest lower risk, guiding monitoring.
Specialist Consultation: Consult a neurologist or cardiologist for result interpretation. Genetic counseling is advised for risk assessment.
Additional Supporting Tests: Cognitive testing, lipid profile, or brain MRI to assess Alzheimer's or heart disease risk.
Test Limitations: APOE variants indicate risk, not diagnosis. Results require clinical correlation with other risk factors.
References: ACMG Alzheimer's Guidelines, 2023; Neurology, Farrer LA, 2022.
